$TSHA News

Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?

Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value

Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

Taysha Gene Therapies Presents Multiple Encore Presentations For Its TSHA-102 Program At 55th Child Neurology Society Annual Meeting

Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

These 3 Risky Stocks Could Be Sitting on 100% Upside

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary

Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...

Taysha Gene Therapies Q2 Earnings Call Highlights

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11